654663-00-0

Usage

Uses

Used in Medicinal and Pharmaceutical Research:
4-(phenylethynyl)piperidine hydrochloride is utilized as a building block for synthesizing biologically active compounds due to its unique structure and potential to contribute to the development of new drugs.
Used in Central Nervous System Depressant Development:
In the pharmaceutical industry, 4-(phenylethynyl)piperidine hydrochloride is considered for its potential as a central nervous system depressant, aiming to provide therapeutic effects for conditions that require sedation or tranquilization.
Used in Analgesic Drug Development:
4-(phenylethynyl)piperidine hydrochloride is being explored as an analgesic agent, capitalizing on its potential to alleviate pain, making it a candidate for pain management therapies.
Used in Neurological and Psychiatric Disorder Treatment:
4-(phenylethynyl)piperidine hydrochloride is studied for its potential therapeutic effects in treating various neurological and psychiatric disorders, highlighting its possible role in future treatments for such conditions.

Upstream product

• 669015-08-1 tert-butyl 4-(phenylethynyl)piperidine-1-carboxylate 
• 591-50-4 iodobenzene 
• 287192-97-6 4-ethynyl-piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1207183-80-9 C₁₈H₂₃N₃O₄ 

Relevant academic research and scientific papers

ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN

The present invention provides compounds that are inhibitors of voltage-gated sodium channels (Nav), in particular Nav 1.7, and are therefore useful for the treatment of diseases treatable by inhibition of these channels, in particular, chronic pain disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

UREA DERIVATIVES AS ANTIBACTERIAL AGENTS

This invention relates to compounds of the Formula (I):or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which is useful for the treatment of diseases or conditions mediated by LpxC.

HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS

Disclosed are the ERK inhibitors of formula 1.0: [Formula (1.0)] and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

PYRROLIDINE DERIVATIVES AS ERK INHIBITORS

Disclosed are the ERK inhibitors of Formula (1.0): and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of Formula (1.0).

2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12.

The invention provides compounds of formula (I) in which L, X, Y, Z1, Z2, R1, R2, R3 and G2 have the meanings defined in the specification; processes for their preparation; pharmaceutical c